for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Incyte's vitiligo treatment meets main goal in late-stage trial

May 17 (Reuters) - Incyte Corp said on Monday its cream, ruxolitinib, to treat pigmentation disorder vitiligo met the main goal in a late-stage study.

The drugmaker said the data will support U.S. and EU regulatory submissions in the second half of 2021. (Reporting by Dania Nadeem in Bengaluru; Editing by Devika Syamnath)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up